Financials data is unavailable for this security.
View more
Year on year Theravance Biopharma Inc had net income fall from a gain of 872.13m to a loss of 55.19m despite a 11.84% increase in revenues from 51.35m to 57.42m.
| Gross margin | -- |
|---|---|
| Net profit margin | -78.18% |
| Operating margin | -69.61% |
| Return on assets | -12.84% |
|---|---|
| Return on equity | -22.88% |
| Return on investment | -13.71% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Theravance Biopharma Inc fell by 258.63m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 27.00m. In addition the company used 32.70m on investing activities and also paid 198.93m in financing cash flows.
| Cash flow per share | -0.9768 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.78 |
|---|---|
| Tangible book value per share | 3.78 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.97 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.1599 |
|---|---|
| Total debt/total capital | 0.1379 |
More ▼
